Interpace Biosciences, Inc. (IDXG)
OTCMKTS · Delayed Price · Currency is USD
0.8600
-0.0610 (-6.62%)
Nov 20, 2025, 11:12 AM EST
Interpace Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 41.92 | 46.93 | 40.04 | 31.84 | 33.12 | 32.4 | Upgrade | |
Revenue Growth (YoY) | -6.06% | 17.21% | 25.75% | -3.86% | 2.22% | 33.77% | Upgrade |
Cost of Revenue | 15.92 | 17 | 14.98 | 13.61 | 14.31 | 21.67 | Upgrade |
Gross Profit | 25.99 | 29.93 | 25.06 | 18.23 | 18.8 | 10.73 | Upgrade |
Selling, General & Admin | 20.73 | 21.14 | 19.6 | 20.1 | 19.88 | 27.45 | Upgrade |
Research & Development | 0.69 | 0.68 | 0.64 | 0.7 | 1.49 | 2.8 | Upgrade |
Amortization of Goodwill & Intangibles | - | - | 0.86 | 1.27 | 3.19 | 4.46 | Upgrade |
Operating Expenses | 21.42 | 21.82 | 21.09 | 22.07 | 24.57 | 34.7 | Upgrade |
Operating Income | 4.57 | 8.11 | 3.96 | -3.84 | -5.76 | -23.98 | Upgrade |
Interest Expense | -0.27 | -0.66 | -1.01 | -1.01 | -1.04 | -0.55 | Upgrade |
Other Non Operating Income (Expenses) | -0.21 | -0.5 | -0.67 | -1.21 | -0.38 | 0.47 | Upgrade |
EBT Excluding Unusual Items | 4.1 | 6.95 | 2.29 | -6.06 | -7.18 | -24.06 | Upgrade |
Merger & Restructuring Charges | - | - | - | - | -0.9 | -2.58 | Upgrade |
Other Unusual Items | - | - | -0.01 | 0.22 | 0.34 | 0.49 | Upgrade |
Pretax Income | 4.1 | 6.95 | 2.28 | -5.84 | -7.74 | -26.15 | Upgrade |
Income Tax Expense | -0 | 0 | 0.02 | 0.03 | -0.71 | 0.05 | Upgrade |
Earnings From Continuing Operations | 4.1 | 6.95 | 2.26 | -5.87 | -7.04 | -26.2 | Upgrade |
Earnings From Discontinued Operations | -0.3 | -0.24 | -0.31 | -16.09 | -7.91 | -0.25 | Upgrade |
Net Income | 3.8 | 6.7 | 1.95 | -21.96 | -14.94 | -26.45 | Upgrade |
Preferred Dividends & Other Adjustments | 0.46 | 0.46 | - | - | - | 3.03 | Upgrade |
Net Income to Common | 3.34 | 6.24 | 1.95 | -21.96 | -14.94 | -29.48 | Upgrade |
Net Income Growth | -44.65% | 242.99% | - | - | - | - | Upgrade |
Shares Outstanding (Basic) | 4 | 4 | 4 | 4 | 4 | 4 | Upgrade |
Shares Outstanding (Diluted) | 33 | 16 | 4 | 4 | 4 | 4 | Upgrade |
Shares Change (YoY) | 654.43% | 260.54% | 2.97% | 2.49% | 2.63% | 7.56% | Upgrade |
EPS (Basic) | 0.75 | 1.42 | 0.45 | -5.18 | -3.61 | -7.32 | Upgrade |
EPS (Diluted) | 0.10 | 0.39 | 0.45 | -5.18 | -3.61 | -7.32 | Upgrade |
EPS Growth | -93.60% | -12.13% | - | - | - | - | Upgrade |
Free Cash Flow | 4.43 | 3.77 | 3.32 | -8.01 | -9.07 | -15.55 | Upgrade |
Free Cash Flow Per Share | 0.13 | 0.24 | 0.76 | -1.89 | -2.19 | -3.86 | Upgrade |
Gross Margin | 62.01% | 63.77% | 62.58% | 57.26% | 56.78% | 33.10% | Upgrade |
Operating Margin | 10.90% | 17.28% | 9.90% | -12.06% | -17.41% | -74.01% | Upgrade |
Profit Margin | 7.96% | 13.29% | 4.88% | -68.97% | -45.12% | -91.01% | Upgrade |
Free Cash Flow Margin | 10.57% | 8.03% | 8.29% | -25.17% | -27.40% | -48.01% | Upgrade |
EBITDA | 4.97 | 8.41 | 4.99 | -1.28 | -0.39 | -18.48 | Upgrade |
EBITDA Margin | 11.86% | 17.92% | 12.46% | -4.02% | -1.18% | -57.03% | Upgrade |
D&A For EBITDA | 0.4 | 0.3 | 1.03 | 2.56 | 5.37 | 5.5 | Upgrade |
EBIT | 4.57 | 8.11 | 3.96 | -3.84 | -5.76 | -23.98 | Upgrade |
EBIT Margin | 10.90% | 17.28% | 9.90% | -12.06% | -17.41% | -74.01% | Upgrade |
Effective Tax Rate | - | 0.06% | 0.74% | - | - | - | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.